Aurobindo Pharma Unit-7 gets 7 USFDA observations
The United States Food and Drug Administration (USFDA) conducted a Current Good Manufacturing Practices (CGMP) inspection at the company's unit-7 manufacturing facility from September 19 to 27, Aurobindo Pharma said in a filing to the BSE.
New Delhi: Drug firm Aurobindo Pharma on Monday said it has received seven observations from the US health regulator for its unit-7 in Telangana.
The United States Food and Drug Administration (USFDA) conducted a Current Good Manufacturing Practices (CGMP) inspection at the company's unit-7 manufacturing facility from September 19 to 27, Aurobindo Pharma said in a filing to the BSE.
Also Read: SEBI slaps fine of Rs 22 crore on Aurobindo Pharma, promoters for insider trading
The inspection ended with seven observations, it added.
"We believe none of the observations are related to data integrity. The company is confident of addressing these issues within the stipulated timeline," Aurobindo Pharma said.
The company, however, did not provide any details about the observations made by the US regulator.
Headquartered in Hyderabad, the company's area of activity includes six major therapeutic/product areas; antibiotics, antiretrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergics
Also Read: Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over the labelling issue
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd